Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682145 | 0.87 | ANPEP (0.55) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL27682147 | 0.87 | ANPEP (0.55) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL14382800 | 0.85 | ANPEP (0.65) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL26503507 | 0.85 | ANPEP (0.65) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL27295441 | 0.84 | KDM4E (0.57) | EPHX1KDM4EGAAALDH1A1MAPT | |
| SCHEMBL27295439 | 0.84 | KDM4E (0.57) | EPHX1KDM4EGAAALDH1A1MAPT | |
| SCHEMBL3250896 | 0.83 | IDO1 (0.65) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL19549091 | 0.83 | IDO1 (0.65) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL12310942 | 0.81 | KDM4E (0.60) | ANPEPEPHX1KDM4EGAAALDH1A1 | |
| SCHEMBL6719511 | 0.81 | ANPEP (0.59) | ANPEPGAAALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531521-B1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | AMANO ENZYME USA LTD (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9498520-B2 | Use of proteases for gluten intolerance | AMANO ENZYME INC. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150182607-A1 | Use of Proteases for Gluten Intolerance | AMANO ENZYME USA CO. LTD. | 2015-07-02 | — | — | US | disclosed |
| US-9011842-B2 | Use of proteases for gluten intolerance | AMANO ENZYME INC. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20130034531-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | AMANO ENZYME USA CO. LTD. | 2013-02-07 | — | — | US | disclosed |
| EP-2531521-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | Amano Enzyme USA., Ltd. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110200574-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | AMANO ENZYME USA CO. LTD. | 2011-08-18 | — | — | US | disclosed |
| WO-2011097266-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | AMANO ENZYME USA, LTD. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20080312212-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1966165-A1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKER | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071400-A1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKER | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-0101653-B1 | LEUCINE DEHYDROGENASE AND A PROCESS FOR PRODUCTION THEREOF | UNITIKA LTD. (JP) | 1988-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200574-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | PREP, ENPEP, PEPD | ANPEP 10/4885EPHX1 948/4885KDM4E 3967/4885 |
| US-20150182607-A1 | Use of Proteases for Gluten Intolerance | PREP, ENPEP, PEPD | ANPEP 10/4885EPHX1 948/4885KDM4E 3967/4885 |
| US-20130034531-A1 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | PREP, ENPEP, PEPD | ANPEP 10/4885EPHX1 948/4885KDM4E 3967/4885 |
| US-20080312212-A1 | Organic Compounds | TRPA1, TRPV1, TRPV3 | ANPEP 4563/4885EPHX1 1431/4885KDM4E 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.